Reproxalap 0.25% was superior to vehicle-control on ocular discomfort symptom score from 80 to 100 minutes after chamber entry. Reproxalap ophthalmic solution 0.25% reached the primary endpoint in a ...
Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution ...
A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback